NCT05349396 - Bioavailability of Eszopiclone 3.0 mg With Regards to Reference Product | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

April 19, 2022

Study Completion Date

April 19, 2022

Conditions

Bioequivalence

Interventions

DRUG

Eszopiclone 3mg Test Drug T-1 Coated Tablets

Participants will receive one tablet of the test formulation T-1 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.

DRUG

Eszopiclone 3mg Test Drug T-2 Coated Tablets

Participants will receive one tablet of the test formulation T-2 containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.

DRUG

Eszopiclone 3mg Reference Product Coated Tablets

Participants will receive one tablet of the Rerefence Product containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.

Trial Locations (1)

600048

Azidus Laboratories Ltd., Chennai